Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy: a multicentre observational study

• Autor(es): Dragoni, G. ; Innocenti, T. ; Amiot, A. ; Castiglione, F. ; Melotti, L. ; Festa, S. ; Savarino, E. V. ; Truyens, M. ; Argyriou, K. ; Noviello, D. ; Molnar, T. ; Bouillon, V. ; Bezzio, C. ; Eder, P. ; Fernandes, S. ; Kagramanova, A. ; Armuzzi, A. ; Oliveira, R. ; Viola, A. ; Ribaldone, D. G. ; Drygiannakis, I. ; Viganò, C. ; Calella, F. ; Gravina, A. G. ; Pugliese, D. ; Chaparro, M. ; Ellul, P. ; Vieujean, S. ; Milla, M. ; Caprioli, F.
• Data: 2024
• Identificador Persistente: http://hdl.handle.net/10400.1/26435
• Origem: Sapientia - Universidade do Algarve
• Tipo de Documento: Objeto de conferência
• Idioma: Inglês
• Contribuidor(es): Sapientia

Descrição

Patients with ulcerative colitis (UC) receiving immunomodulators are at substantial risk of colectomy. Since robust evidence regarding the post-operative outcomes of patients treated with anti-JAKs in the pre-operative phase is lacking, we aimed to assess the risk of complications of tofacitinib exposure prior to colectomy in comparison with anti-TNFs, vedolizumab, and ustekinumab.